Skip to content

Cranberry product versus low dose trimethoprim in the prevention of recurrent urinary infections in older women: a double blind randomised trial of effectiveness and acceptability

Cranberry or trimethoprim for the prevention of recurrent urinary tract infections? A randomized controlled trial in older women

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN80031108
Enrollment
120
Registered
2006-06-13
Start date
2006-09-01
Completion date
Unknown
Last updated
2018-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent urinary tract infections Urological and Genital Diseases Urinary tract infections

Interventions

Trimethoprim 100 mg daily versus 500 mg cranberry product daily

Sponsors

University of Dundee (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Community dwelling women aged 45 years or over with at least two antibiotic-treated urinary tract infections or episodes of cystitis in the previous 12 months

Exclusion criteria

Exclusion criteria: 1. Previous urological surgery, stone or anatomical abnormalities 2. Urinary catheter 3. Diabetes mellitus 4. Immunocompromised 5. Pyelonephritis 6. Severe renal impairment 7. Blood dyscrasia 8. Symptomatic urinary tract infection (UTI) at baseline 9. Cognitive impairment precluding informed consent 10. Resident in institutional care 11. On longterm antibiotics 12. On warfarin therapy 13. Regular cranberry consumers 14. Unwilling to participate

Design outcomes

Primary

MeasureTime frame
Current primary outcome measure (as of 21/02/2018:) First recurrence of symptomatic urinary tract infection self reported by patient during 6 month study Previous primary outcome measure: First recurrence of symptomatic urinary tract infection

Secondary

MeasureTime frame
Current secondary outcome measures (as of 21/02/2018): Acceptability and adherence, measured by number of capsules left at the end of the 6 month study Previous secondary outcome measure: Acceptability and adherence

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026